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ABSTRACT
Objective: Recombinant human growth hormone (GH) and pioglitazone (PIO) in abdominally
obese adults with impaired glucose tolerance were evaluated under the hypothesis that the
combination attenuates GH-induced increases in glucose concentrations, reduces visceral
adipose tissue (VAT), and improves insulin sensitivity over time.
Design: Randomized, double-blind, placebo-controlled, 2 3 2 factorial design.
Setting: Veterans Affairs Palo Alto Health Care System, Palo Alto, California, United States.
Participants: 62 abdominally obese adults aged 40–75 with impaired glucose tolerance.
Interventions: GH (8 lg/kg/d, or placebo) and pioglitazone (30 mg/d, or placebo) for 40 wk.
Outcome Measures: Baseline and after 40 wk of treatment, VAT content was quantified by
CT scan, glucose tolerance was assessed using a 75-g oral glucose tolerance test, and insulin
sensitivity was measured using steady-state plasma glucose levels obtained during insulin
suppression test.
Results: Baseline: body mass index (BMI), plasma glucose, and visceral fat content were
similar. 40 wk: visceral fat area declined 23.9 6 7.4 cm
2 in GH group, mean difference from
placebo:  28.1 cm
2 (95% CI  49.9 to  6.3 cm
2; p ¼ 0.02). Insulin resistance declined 52 6 11.8
mg/dl with PIO, mean difference from placebo of 58.8 mg/dl (95% CI  99.7 to 18.0 mg/dl; p
¼0.01). VAT and SSPG declined with GH and PIO combined, mean differences from placebo of
 31.4 cm
2 (95% CI  56.5 cm
2 to  6.3 cm
2; p ¼ 0.02) and  55.3 mg/dl (95% CI  103.9 to  6.7
mg/dl; p ¼ 0.02), respectively. Fasting plasma glucose increased transiently in GH group. No
significant changes in BMI were observed.
Conclusions: Addition of PIO to GH attenuated the short-term diabetogenic effect of GH; the
drug combination reduced VAT and insulin resistance over time. GH plus PIO may have added
benefit on body composition and insulin sensitivity in the metabolic syndrome.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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PLoS CLINICAL TRIALSINTRODUCTION
Overweight adults with impaired glucose tolerance (IGT)
have a 5%–10% risk of developing diabetes per year, and
insulin resistance in the context of inadequate beta cell
compensation is an important cause of progression to
diabetes [1]. Weight loss has been shown to improve insulin
sensitivity and prevent or delay progression to diabetes [2–5].
According to recent studies, the improvement in insulin
sensitivity that occurs with weight loss is closely linked to the
reduction of visceral adipose tissue (VAT), the collection of
intra-abdominal adipose depots that includes omental and
intrahepatic fat [6–7]. After controlling for body mass index
(BMI), whole body and subcutaneous fat, only VAT is an
independent predictor of endogenous insulin sensitivity and
glucose metabolism before or after weight loss [8–10]. This, in
turn, suggests that reducing visceral fat is crucial to
improving insulin sensitivity and preventing diabetes in
high-risk individuals.
Recombinant human growth hormone (GH) is a lipolytic
drug that reduces total body, abdominal, and visceral fat in
GH-deﬁcient adults [11–13]. Several studies have reported as
much as 25%–45% reductions in VAT following GH replace-
ment in this population [14–16]. Like GH deﬁcient adults,
abdominally obese individuals have increased VAT and
insulin resistance, and continuous 24-hour measurements
indicate that GH levels are below normal [17]. Recent studies
suggest that GH improves insulin sensitivity when adminis-
tered over time in men with large waist circumferences
(WCs), and this improvement has been indirectly attributed
to visceral fat reduction [18–21]. The potential beneﬁt of
long-term GH administration on insulin sensitivity contrasts
with our traditional understanding of direct GH-induced
antagonism of insulin action, particularly during acute
treatment [13,22]. While GH has been extensively studied in
adults who were normoglycemic at baseline, less is known
about the short- and long-term effects of GH in adults with
IGT or diabetes.
In obese type 2 diabetics, insulin-sensitizing drugs known
as thiazolidinediones (TZDs) also have been reported to
reduce visceral fat and improve insulin sensitivity [23]. The
combination of a TZD and GH in rodents was shown to
counter the short-term, transient diabetogenic effect of GH
and reduce both visceral adiposity and insulin resistance over
time [24–25]. Similar studies assessing the combined use of a
TZD and GH in humans have not been performed.
The purpose of this study was to determine the effects of
GH and the TZD pioglitazone (PIO) alone and in combina-
tion on glucose metabolism, visceral adiposity, and insulin
sensitivity in abdominally obese adults with IGT. We
hypothesized that (1) compared to GH alone, treatment with
GH plus PIO would result in better short-term glucose
metabolism; and (2) compared to placebo, treatment with GH
plus PIO would lead to greater reductions in both VAT and
insulin resistance over time.
METHODS
Participants
A total of 81 overweight adult men and women were enrolled
in the study. They were recruited between March 2003 and
March 2004 using ﬂiers posted at medical centers and other
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Editorial Commentary
Background: People who are overweight are at higher risk of
developing type 2 diabetes, particularly if they have impaired glucose
tolerance (IGT). When an individual has IGT, their cells are not able to
respond properly to insulin in the blood, which means that blood sugar
levels can remain high, and fat cells do not take up fatty acids from
blood at the rate they should. The term prediabetes is often used to
refer to these linked characteristics. However, if such individuals are able
to lose weight they can reduce their chances of becoming diabetic in
the future. In particular, loss of a particular type of fat, the visceral fat
(packed in around the internal organs, as opposed to fat immediately
under the skin), is thought to be beneficial for people at risk of
developing type 2 diabetes. Some researchers have suggested that
giving human growth hormone (GH) to people who are overweight
might help reduce their levels of visceral fat. At the same time, drugs
known as thiazolidinediones are currently used, in combination with
other drugs, diet, and exercise, as a treatment for type 2 diabetes. The
researchers carrying out this study wanted to find out whether
combining treatment with human GH and a thiazolidinedione,
pioglitazone (PIO), would reduce levels of visceral fat and improve
glucose metabolism in overweight adults with IGT. The researchers
specifically planned to compare the changes in these primary outcomes
amongst people receiving both human GH and PIO for 40 weeks with
the changes in individuals receiving placebo only; additional compar-
isons were also done for individuals receiving either drug alone, as
compared to placebo.
What this trial shows: A total of 76 participants were randomized and
received the treatment allocated to them, but only 62 participants were
included in the final analyses due to losses to follow-up. The primary
outcomes being compared at baseline and after 40 weeks of treatment
were the change in visceral fat levels and change in individuals’
sensitivity to insulin. Individuals receiving GH experienced a drop in
visceral fat area over the 40 weeks of the trial, as compared to placebo,
whilst PIO alone did not seem to have an effect on visceral fat area.
Individuals receiving both GH and PIO, however, also showed a decrease
in visceral fat area. When examining the effect on insulin resistance, GH
alone did not seem to have an effect on the ability to respond to insulin.
However, administration of PIO alone did bring about a decrease in
insulin resistance levels, as compared to placebo, and individuals
receiving both GH and PIO together also experienced a drop in insulin
resistance. The trial was not designed to detect statistically significant
differences in side effects between the groups studied, but some side
effects, such as build-up of fluid in the limbs and joint stiffness, seemed
to be more common in the groups receiving drug treatment than in the
placebo group.
Strengths and limitations: Although the trial was small, enough
participants were recruited to detect statistically significant changes in
the primary outcomes. Strengths of the trial include the use of
appropriate techniques to conceal the randomization sequence from
investigators recruiting participants into the trial and blinding of both
participants and investigators to the treatments that an individual
would receive. However, one limitation includes the fact that the
likelihood of developing diabetes was not directly measured as an
outcome in this trial, and it is therefore not possible to conclude from
these results that administration of GH, PIO, or both combined, will help
prevent diabetes amongst overweight people with IGT. Finally, this trial
compared the drug interventions directly with placebo and not with
behavioral interventions such as diet and exercise, which are normally
recommended for the prevention of diabetes amongst overweight
people. It would be important to further investigate the efficacy, harms,
and costs of these drugs directly against nondrug interventions before
making any recommendations about their clinical use.
Contribution to the evidence: Other studies have shown that PIO
administration has beneficial effects on insulin sensitivity in people with
type 2 diabetes. This study adds evidence confirming that PIO is likely to
have similar effects in people who are not diabetic but who are
overweight and who have IGT. The study also adds data regarding the
effect of PIO and GH combined in such populations; giving both drugs
together seemed to have beneficial effects on visceral fat area and
insulin sensitivity, as compared to placebo.
The Editorial Commentary is written by PLoS staff, based on the reports of the
academic editors and peer reviewers.facilities throughout the San Francisco Bay Area. Speciﬁc
criteria for inclusion were age between 40 and 75 years, BMI
  27 kg/m
2, and WC . 100 cm for men and . 88 cm for
women. As part of the screening visit, a 75-g oral glucose
tolerance test (OGTT) was performed following a ten- to 12-h
overnight fast. Participants with IGT (fasting plasma glucose
[FPG] ,125 mg/dl and 2-h postprandial glucose ¼ 140–200
mg/dl) were enrolled. Respondents were not eligible to
participate if diabetes was known to exist or a screening
OGTT revealed either a FPG   126 mg/dl or 2-h postprandial
glucose (PPG)   200 mg/dl that was repeated and conﬁrmed
on separate day. Other exclusion criteria included the
following: known history of malignancy or congestive heart
failure; recent treatment with weight-reducing medications
or corticosteroids in doses exceeding standard replacement;
or being of child-bearing potential and either breastfeeding
or declining contraception throughout the treatment period.
In addition, respondents with a history of acromegaly or
clinically signiﬁcant cardiac, pulmonary, hepatic, or renal
disease, serum alanine aminotransferase (ALT) more than
three times above the upper normal limit, or uncontrolled
hypertension were excluded.
Study Design
The total treatment period for this randomized, double-
blind, double-dummy, parallel group study with a 2 3 2
factorial design was 40 wk. A combination of two drugs was
used: PIO (Actos 30 mg/d, Takeda Pharmaceuticals, http://
www.tpna.com) or its placebo and recombinant human GH
(Nutropin AQ 8 lg/kg/d, Genentech, http://www.gene.com) or
its placebo. Enrolled participants were randomly assigned by
a third-party investigator to receive one of the following
treatment combinations: GH þ PIO, GH þ PIO placebo, GH
placebo þ PIO, or GH placebo þ PIO placebo (Table 1). All
testing and follow-up were conducted at the Clinical Studies
Unit of the Veterans Affairs Palo Alto Health Care System,
Palo Alto, California. Ethical approval for this study was
provided by the Administrative Panel on Human Subjects in
Medical Research at Stanford University, and all participants
provided written informed consent.
Randomization: Sequence Generation
Generation of the randomization sequence was performed at
the ofﬁce of a third-party investigator not afﬁliated with the
study. Permuted blocks and stratiﬁcation by BMI, gender, 2-h
postprandial glucose (after 75-g oral glucose challenge), and
estrogen repletion status of women were used.
Randomization: Allocation Concealment
The randomization list generated in the ofﬁce of the third-
party investigator was forwarded to an investigational
pharmacist, who dispensed medications. All randomization
assignments were sequentially numbered and placed in sealed
opaque envelopes. Assignment codes were fully concealed
until after all recruitment, testing, and data analyses were
complete.
Randomization: Implementation
After being evaluated for eligibility at screening, participants
who met criteria for inclusion into the study were assigned a
code comprising a number and three letters. The number
corresponded to the order of each participant’s enrollment
into the study. This code was forwarded along with relevant
information for stratiﬁcation to the third-party investigator.
The structure of the sequence of randomization was unknown
to the researchers involved with the study. Randomization
assignment for each participant was forwarded only to the
investigational pharmacist, who dispensed all medications.
Masking
Given the double-blind, placebo-controlled nature of the
study, all participants and investigators were blinded to
group assignment until after the study was completed and
data were analyzed. The manufacturers of recombinant
human GH and PIO provided matching placebos that were
indistinguishable from the active medications. Medication
seals, labels, and containers were utilized in a uniform fashion
to preserve the study blind.
Sample Size
Sample size was determined using data from Johannsson et al.
[19], in which nine months of GH resulted in a 17.9% 6 3.5%
reduction in visceral fat along with an improvement in insulin
sensitivity in abdominally obese men. Using this information,
we determined that 12 participants were needed per group to
have an 80% chance of detecting a change in visceral fat of at
least 17.9%. However, since women were also included in the
study and are known to respond less effectively to GH than
men, we increased the sample size to 15.
Outcomes
The primary outcome measures were change in visceral fat
content and change in insulin sensitivity. At baseline (wk 0)
and after 40 wk of total treatment, computed tomography
(CT)-scan measurements were performed to quantify visceral
fat area. Baseline versus post-treatment insulin sensitivity was
assessed using a 3-h insulin suppression test.
Secondary outcome measures included assessments of
short- and long-term glucose metabolism, BMI, and anthro-
pometric measurements. FPG was measured monthly, and
baseline versus post-treatment glucose tolerance was meas-
ured using a 3-h OGTT. Glycohemoglobin was measured at
baseline and every three months thereafter at the clinical
laboratory of the Veterans Affairs Palo Alto Health Care
System. Body weight was measured monthly, and measure-
ments of WC and waist-to-hip ratio (WHR) were performed at
baseline and again at week 40.
.......................................................................................................................................................................................
Table 1. Treatment Assignment of Participants
Period Placebo PIO GH GH þ PIO
Weeks 0–4 (PIO run-in) PIO placebo PIO 15 mg/d PIO placebo PIO 15 mg/d
Weeks 5–40 PIO placebo plus GH placebo PIO 30 mg/d plus GH placebo PIO placebo plus GH 8 lg/kg/d PIO 30 mg/d plus GH 8 lg/kg/d
doi:10.1371/journal.pctr.0020021.t001 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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performed on separate days following a 3- to 4-wk washout of
study drugs. A drug washout was used to facilitate a direct
assessment of the relationship between change in body
composition and change in glucose disposal over time
without the potential confound of direct drug effects on
these measurements.
Ancillary Tests
Lipids were measured using available stored serum samples
from baseline and post-treatment visits. This was the only
analysis performed that was not prespeciﬁed in the protocol.
Samples from participants who began treatment with lipid-
lowering medications anytime during or shortly before their
participation in the study were not assessed for lipid
measurements. Triglycerides, HDL cholesterol, and total
cholesterol were measured directly, and LDL cholesterol
was calculated based on the method described by Friedewald
et al. [26]. Measurements were performed in the clinical
laboratory of the Veterans Affairs Palo Alto Health Care
System.
Safety Measures
Participants were followed monthly as outpatients and had a
complete physical examination at each visit. Each participant
was examined for treatment-related side effects, including
peripheral edema or other ﬂuid retention symptoms. Serum
insulin-like growth factor 1 (IGF-1) levels were obtained at
baseline and every two months after starting injections until
the end of the treatment period (week 40). An immunoche-
miluminometric assay in a reference laboratory (LabCorp,
http://www.labcorp.com) was used to measure serum IGF-1.
ALT levels were obtained at baseline and every 2 mo
thereafter.
Dose adjustments for either GH or PIO were made if any of
the following occurred during treatment: FPG . 140 mg/dl
without associated symptoms, serum IGF 1 exceeding the
upper normal reference limit for young adults, or ﬂuid
retention symptoms such as arthralgias, or carpal tunnel
syndrome. Participants were discontinued if any of the
following occurred during treatment: symptoms associated
with FPG increase, an increase in serum ALT to more than
three times the upper reference limit, congestive heart
failure, or persistence of side effects despite GH or PIO dose
reduction.
Diet, Exercise, and Activity
Participants were asked to adhere to their usual daily dietary
consumption and exercise routine for the duration of the
study. They were instructed to report any signiﬁcant changes
in dietary intake or physical activity.
Anthropometric Measurements
Weight was measured to the nearest 0.1 kg on a standard
scale, and height was measured in centimeters using a wall-
mounted stadiometer. BMI was calculated as the body weight
(kg) divided by the height (m
2). A standard tape measure was
used to quantify waist and hip circumferences as well as the
WHR ratio. WC was obtained while the participant was
supine and with the tape measure placed at the level of the
umbilicus. Hip circumference was obtained while the
participant was standing and with the tape measure placed
at the level of greatest gluteal protrusion observed from the
side of the participant.
CT Scan of the Abdomen
A noncontrast CT scan was performed to quantify abdominal
subcutaneous and visceral fat area. This imaging technique is
among the most reliable for measuring visceral fat [27]. With
the individual in a supine position, a preliminary scout ﬁlm of
the abdomen and pelvis was obtained to identify anatomic
landmarks. A 0.8-mm thick CT slice was obtained at the level
of the L4–5 lumbar disc, as visceral fat area at L4–5 has been
shown to correlate with total visceral fat volume. Fat content
was represented in Hounsﬁeld units in the range of  150 to
 50, and visceral fat and subcutaneous fat regions were
identiﬁed as described previously [28]. All fat measurements
were performed using Image J Software, National Institutes of
Health, (http://rsb.info.nih.gov/ij) and are recorded in centi-
meters squared. A single General Electric LightSpeed
Scanner (http://www.ge.com) at the Veterans Affairs Palo Alto
Health Care System was used to perform all baseline and
week-40 CT scans.
OGTT
After an overnight fast lasting ten to 12 hours, participants
arrived at the Clinical Studies Unit and had an FPG
measurement. Participants then ingested a 75-g oral glucose
beverage and had additional plasma glucose measurements 30
min, 60 min, 120 min, and 180 min after beverage ingestion.
All glucose measurements were performed using an on-site
glucose analyzer (Analox Instruments, http://www.analox.
com). Specimens were centrifuged immediately, and the on-
site analyzer was calibrated daily. The ﬁve OGTT glucose
measurements were used to calculate the glucose area under
the curve (AUC) by the trapezoidal method.
Insulin Suppression Test
Insulin sensitivity was measured using a three-hour insulin
suppression test [29–31]. After fasting for ten to 12 h,
participants arrived at the Clinical Studies Unit and an
intravenous catheter was placed into each antecubital vein.
One catheter was used to draw blood for glucose measure-
ments, and the catheter in the contralateral arm was used for
infusion of octreotide, insulin, and 20% dextrose solutions.
The three infused substances were administered simultane-
ously. Octreotide acetate (Sandostatin, Novartis Pharmaceut-
icals, http://www.novartis.com) was used to suppress
endogenous secretion of insulin and was infused at 0.27 lg/
m
2/min. Insulin was infused at 32 mU/m
2/min, and 20%
dextrose was infused at 267 mg/m
2/min. Plasma glucose was
measured every 30 minutes for the ﬁrst 150 min and then
every 10 min during the last half hour of the test. The last
four serum glucose measurements were then averaged and
constituted the individual’s SSPG. The SSPG provides a direct
measure of insulin-mediated glucose uptake and can be used
to describe each individual’s insulin sensitivity [29–31].
Statistical Methods
Using all available data from all participants who had a
follow-up measurement of visceral fat area and insulin
sensitivity, regardless of adherence to treatment, a modiﬁed
intention-to-treat analysis was used to evaluate data. The last
available postrandomization value obtained prior to a
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GH and TZD in Obese Prediabetic Adultsmissing measurement was carried forward for the missing
data. Data were analyzed using GB-Stat statistical software for
Macintosh (Dynamic Microsystems, http://www.gbstat.com/
macintosh/index1.htm). Data for primary and secondary
analyses are expressed as the mean 6 standard error of the
mean (SEM). One-way ANOVA was used to compare baseline
values of the participant groups. For measurements pertain-
ing to visceral fat, anthropometrics, insulin sensitivity,
glucose and lipoprotein metabolism, ANOVAs for repeated
measures were used to analyze differences between data
obtained at all time points. Pearson’s correlation coefﬁcient
was used to determine the relationship between change in
VAT and change in insulin sensitivity. Results are considered
statistically signiﬁcant at p , 0.05.
RESULTS
Participant Flow
We randomized 81 participants to one of four treatment
groups (Figure 1). There were 19 African Americans, ﬁve
Hispanics, two Paciﬁc Islanders, two Asians, and 53 individ-
uals of European descent. A total of 76 participants received
Figure 1. Screening, Randomization, and Follow-Up
aFPG reverted to pretreatment levels within 1 mo after stopping GH.
bIndicated at week 12 that they could no longer adhere to follow-up schedule for personal reasons.
cReported as a renal cell carcinoma after removal. In a CT scan done before GH was initiated, the solitary mass appeared completely unchanged and was
indistinguishable from colon.
dDid not have a follow-up CT scan and 3-h insulin sensitivity test after an overnight fast.
doi:10.1371/journal.pctr.0020021.g001
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baseline, no signiﬁcant differences in age, BMI, gender,
estrogen status of female participants, or glucose levels were
present between the groups (Table 2). A total of 19 withdrew
or were lost to follow-up, and postrandomization measures of
visceral fat and insulin sensitivity after a conﬁrmed overnight
fast were not obtained. We gave follow-up tests of visceral
adiposity and insulin sensitivity to 62 participants, and these
were included in the ﬁnal data analyses. Group assignment,
follow-up, and withdrawals are shown in Figure 1.
Outcomes and Estimation
Primary outcome measures: VAT. As shown in Figure 2, 40
wk of GH treatment resulted in signiﬁcant reductions in
visceral fat area. After 40 wk of treatment, visceral fat area
declined 23.9 6 7.4 cm
2, a mean difference of  28.1 cm
2
compared with placebo (95% conﬁdence interval [CI]  49.9
cm
2 to 6.3 cm
2; p¼0.02) (Table 3). A similar decline in VAT
was seen in the GHþPIO group versus placebo, with a mean
difference of  31.4 cm
2 (95% CI  56.5 cm
2 to  6.3 cm
2; p ¼
0.02). The corresponding percentage declines in visceral fat
in the GH and GH þ PIO groups were 13.1% and 16.6%,
respectively, indicating the lipolytic effect of GH on this
adipose tissue depot. In contrast, VAT area did not decline
signiﬁcantly in the PIO group (6.4%).
Primary outcome measures: Insulin sensitivity. Treatment
with PIO improved endogenous insulin sensitivity in abdomi-
nally obese, insulin-resistant individuals with IGT, as seen in
Figure 3. Insulin resistance, assessed by SSPG, declined 52 6
11.8 mg/dl with PIO, a mean difference of  58.8 mg/dl
compared with placebo (95% CI 99.7 mg/dl to 18.0 mg/dl; p
¼0.01) (Table 3). Similarly, SSPG declined when both GH and
PIO were combined, with a mean difference compared with
placebo of 55.3 mg/dl (95% CI 103.9 to 6.7 mg/dl; p¼0.02).
The corresponding percentage reductions for SSPG in the
PIO and GH þ PIO groups were similar: 21.4% in the PIO
group and 19.6% in the GH þ PIO group. This indicates an
important role for PIO in ameliorating insulin resistance.
Despite a reduction in visceral fat content, SSPG did not
decline signiﬁcantly following prolonged GH treatment
(8.8%).
Secondary outcome measures and ancillary tests: Serum
IGF-1 levels. At baseline, serum IGF-1 levels were similar
betweentreatmentgroups(Figure4).AfterninemonthsofGH
treatment, serum IGF-1 in the GH group increased to 262.2 6
35.1 ng/ml (an increase of 145.9 6 33.3 ng/ml above baseline
IGF-1) and to 256 6 36.2 ng/ml in the GH þ PIO group (an
increase of 112.1 6 34.8 ng/ml above baseline IGF-1). In both
GH-treated groups, the IGF-1 increases generally did not
exceed 2 standard deviations above the age-adjusted reference
mean (unpublished data). No within-group changes in serum
IGF-1 occurred in the placebo or PIO groups over time.
BMI, Anthropometrics, and Other CT Measurements
The effects of treatments on body composition are summar-
ized in Table 4. No signiﬁcant changes in subcutaneous fat
area were seen among the treatment groups. In addition,
BMI, WC, and WHR did not change signiﬁcantly in any of the
treatment groups, except for a 7.0% decline in WHR that
occurred in the GH þ PIO group.
Glucose Metabolism and Lipids
The effects of treatments on short- and long-term glucose
concentrations are summarized in Table 4. In the GH group
only, FPG increased from 104.7 6 2.8 mg/dl to 116.8 6 3.9
mg/dl at week 12 (p , 0.01) (Figure 5). However, mean
glycohemoglobin levels for all groups did not change
signiﬁcantly during follow-up. In addition, baseline versus
post-treatment mean glucose area under the curve were
similar for all treatment groups. Based on the ﬁnal OGTT
(performed after a 3- to 4-wk drug washout for both GH and
PIO), two participants in the placebo group and two
.......................................................................................................................................................................................
Table 2. Characteristics of Participants at Baseline
Variable Placebo PIO GH GH þ PIO p-Value
a
Number of participants 19 (16) 22 (15) 19 (16) 21 (15)
Number of females 6 (5) 9 (6) 7 (5) 8 (5)
Age (y) 55.1 6 8.5 (55.4 6 9.0) 54.5 6 8.1 (54.7 6 8.5) 55.1 6 10.5 (55.3 6 9.6) 49.5 6 9.7 (52 6 7.5) 0.15 (0.68)
BMI (kg/m
2) 34.5 6 5.8 (35.1 6 5.7) 36.9 6 5.5 (36.6 6 4.7) 37.4 6 8.1 (37.4 6 8.7) 38.0 6 7.7 (36.6 6 6.9) 0.41 (0.80)
FPG (mg/dl) 106.3 6 13.1 (106.1 6 14.2) 106.7 6 13.5 (107.4 6 14.1) 105.1 6 11.5 (104.7 6 12.0) 110.1 6 12.1 (108.4 6 13.7) 0.62 (0.89)
PPG (mg/dl) 164.5 6 22.9 (169.4 6 20.3) 169.1 6 28.9 (162.7 6 29.9) 169.4 6 28.6 (163.8 6 26.4) 162.7 6 17.9 (161.8 6 17.5) 0.78 (0.81)
WC (cm) 113.3 6 15.6 (114.0 6 16.4) 113.6 6 12.9 (113.7 6 12.4) 115.2 6 18.2 (116.9 6 19.2) 116.4 6 10.2 (114.8 6 10.3) 0.90 (0.93)
WHR 0.99 6 0.045 (1.00 6 0.045) 0.97 6 0.089 (0.97 6 0.092) 0.97 6 0.085 (0.98 6 0.078) 0.99 6 0.07 (1.00 6 0.067) 0.63 (0.69)
Values are for all randomized participants; values in parentheses are for participants included in final analyses. Values are means 6 standard deviation.
aFor comparison of baseline data for four treatment groups using one-way ANOVA.
PPG, plasma glucose two hours after 75-g oral glucose challenge.
doi:10.1371/journal.pctr.0020021.t002 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Figure 2. Change in VAT Area after 40 Weeks of Treatment with GH and/
or PIO in Abdominally Obese Adults with IGT
*p ¼ 0.01 for within-group comparison of VAT area at week 40 versus
baseline. **p ¼ 0.03 for comparison of VAT areas for four treatment groups
combined using analysis of variance for repeated measures. Values are means
6 SEM.
doi:10.1371/journal.pctr.0020021.g002
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GH and TZD in Obese Prediabetic Adultsparticipants in the PIO groups had newly diagnosed diabetes.
No new cases of diabetes were identiﬁed in either GH-treated
group at the end of the study.
Although lipid testing was not prespeciﬁed in the protocol,
measurement of lipids was performed using available stored
serum samples. No signiﬁcant differences in baseline versus
post-treatment triglycerides, HDL cholesterol, LDL choles-
terol, or total cholesterol were seen between the four
treatment groups (Table 5).
Correlations of SSPG Changes with Body Composition
Findings
When participants from all four treatment groups were
combined, change in SSPG was most directly related to
change in VAT (r ¼ 0.425, p , 0.001). There were no other
signiﬁcant correlations between SSPG and subcutaneous fat,
BMI, anthropometric measurements, or measurements of
glucose and lipoprotein metabolism.
Adverse Events
Side effects observed in the trial are fully summarized in this
section and in Table 6. Side effects were generally mild and
related to ﬂuid retention. Fluid retention symptoms resolved
in all cases either spontaneously or following a dose
reduction in GH or PIO. In addition, ﬁve participants in
the GH group experienced transient increases in fasting
glucose concentrations about 4–8 wk after starting injections.
The glucose increases were not associated with symptoms and
resolved either spontaneously (two participants), after a 25%
reduction in GH dose (two participants), or after GH was
brieﬂy held for 3–4 wk (one participant). Except in the latter
case, glucose increases above baseline were modest and did
not exceed 5–15 mg/dl. No new cases of diabetes were
identiﬁed in either GH-treated group after 40 wk of treat-
ment. During follow-up, no signiﬁcant change in ALT was
seen in any group (unpublished data).
DISCUSSION
Interpretation
In the present study, nine months of treatment with GH
resulted in a reduction in VAT. The well-established lipolytic
effect of GH has been attributed to suppression of lip-
oprotein lipase activity or enhanced responsiveness of
.......................................................................................................................................................................................
Table 3. Mean Change (6 SEM) in VAT and Insulin Sensitivity by Treatment Group
Measurement Group
a Mean Change Mean Difference Group
Versus Placebo (95% CI)
Effect Size Group
Versus Placebo (95% CI)
L4 5 VAT area (cm
2) Placebo (n ¼ 16) 4.2 6 8.1
PIO (n ¼ 15)  10.5 6 8.0  14.7 ( 37.6 to 8.2) 0.46 ( 0.26 to 1.17)
GH
b (n ¼ 16)  23.9 6 7.4  28.1 ( 49.9 to  6.3) 0.91 (0.16–1.61)
GH þ PIO
b (n ¼ 15)  27.2 6 9.5  31.4 ( 56.5 to  6.3) 0.91 (0.15–1.62)
SSPG (mg/dl) Placebo (n ¼ 16) 6.8 6 15.9
PIO
c (n ¼ 15)  52.0 6 11.8  58.8 ( 99.7 to  18.0) 1.06 (0.28–1.78)
GH (n ¼ 16)  19.9 6 16.6  26.7 ( 73.1 to 19.7) 0.42 ( 0.30 to 1.10)
GH þ PIO
b (n ¼ 15)  48.5 6 17.8  55.3 ( 103.9 to  6.7) 0.84 (0.08–1.55)
Results were obtained 3–4 weeks after drug washout.
ap ¼ 0.03 for comparison of mean changes of four treatment groups using one-way analysis of variance.
bp ¼ 0.02 for comparison of mean change in treatment group versus placebo.
cp ¼ 0.01 for comparison of mean change in treatment group versus placebo.
doi:10.1371/journal.pctr.0020021.t003 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Figure 3. Change in SSPG after 40 Weeks of Treatment with GH and/or
PIO in Abdominally Obese Adults with IGT
Values are means 6 SEM. *p¼0.001 and 0.01, respectively, for PIO group and
GH þ PIO group for within-group comparison of week 40 versus baseline
SSPG. **p¼0.03 for comparison of SSPG for four treatment groups combined
using analysis of variance for repeated measures.
doi:10.1371/journal.pctr.0020021.g003
Figure 4. Effects of Four Different Interventions on Serum IGF-1 in
Abdominally Obese Adults with IGT
Values are means 6 SEM. *p , 0.01 for within-group comparison of IGF-1 at
follow-up versus baseline time points. **p , 0.001 for comparison of IGF-1
values for four treatment groups combined using analysis of variance for
repeated measures.
doi:10.1371/journal.pctr.0020021.g004
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GH and TZD in Obese Prediabetic Adultsadipocytes to catecholamine [20,32–34]. Fasting glucose
increased during the ﬁrst four to eight weeks of GH
treatment, but this resolved either spontaneously or shortly
after GH dose reduction. No signiﬁcant differences between
baseline and post-treatment FPG and OGTT-derived glucose
area under the curve were seen following prolonged GH
administration. Lipoprotein levels did not change despite a
signiﬁcant reduction in visceral fat content. Although lipid
measurements were performed after a three-week washout of
study drug, possibility altering the beneﬁt on lipids, trials
assessing the effects of prolonged GH administration on
lipids have yielded conﬂicting results [19,20, 35–37].
Insulin sensitivity did not improve after nine months of GH
despite VAT reduction. Although GH is known to impair
insulin action directly by reducing phosphorylation of insulin
receptor substrate-1 (IRS-1) and IRS-2 proteins [38,39], a long
drug washout was used to reduce possible confounding
effects of GH and IGF-1 on glucose disposal [40]. A possible
explanation for the lack of SSPG change is that visceral fat
declined 13.1% in the GH group, less than the 18% reduction
in visceral fat that was associated with an improvement in
insulin sensitivity in Johannsson et al. [19]. Unlike the
previous investigation, our sample included ﬁve women
(approximately one-third of the total sample), and GH-
treated women are known to achieve smaller reductions in
visceral and subcutaneous fat than men [41–43]. The
diminished effect of GH on body composition in women
has been attributed to the estrogen-induced antagonism of
GH action [41–43]. In addition, although mean BMI did not
change and participants were asked to adhere to their usual
diet and exercise routine, dietary and lifestyle factors are a
potential confound. The lack of rigorous monitoring pre-
cluded the maintenance of a stable weight in all participants,
and weight gain did occur in individual cases. It has been
reported that the lipolytic effect of GH is blunted in
individuals who experience weight gain as a result of
increased dietary intake or decreased exercise, or both [20].
We found that 40 weeks of PIO improved insulin sensitivity
in individuals with IGT. As with patients with type 2 diabetes
[44], the insulin-sensitizing effect of PIO persisted several
weeks after the drug was stopped in PIO-treated individuals.
However, no signiﬁcant change in body composition, includ-
ing visceral or subcutaneous fat content, was seen.
In vitro and in vivo studies have indicated that activation of
peroxisome proliferator-activated receptors gamma with
TZDs improves insulin sensitivity by modulating the expres-
sion of various genes in the insulin-signaling pathway and
increasing the production of glucose transporter proteins
[45–47]. Miyazaki et al. recently suggested that PIO’s
beneﬁcial effect on insulin action in type 2 diabetes might
be related to a change in body composition [23]. The authors
indicated that a shift in body fat from visceral to subcuta-
neous fat depots was observed following 16 weeks of PIO, and
the change was associated with an improvement in hepatic
and peripheral insulin sensitivity. The greater reduction in
visceral fat reported in Miyazaki et al. [23] may have been
related to the makeup of the study population (patients with
type 2 diabetes versus those with IGT) or the use of a higher
PIO dose (45 mg/d instead of 30 mg/d). However, other
investigators reported no change in visceral fat content in
.......................................................................................................................................................................................
Table 4. Secondary Outcome Measures Related to Body Composition and Glucose Metabolism
Measurement Time Placebo PIO GH GH þ PIO
L4 5 subcutaneous fat area (cm
2) Baseline 407 6 32 (n ¼ 16) 494 6 39 (n ¼ 15) 460 6 52 (n ¼ 16) 481 6 44 (n ¼ 15)
Week 40 424 6 33 505 6 40 434 6 47 473 6 51
BMI (kg/m
2) Baseline 35.2 6 1.4 (n ¼ 16) 36.6 6 1.2 (n ¼ 15) 37.4 6 2.2 (n ¼ 16) 36.6 6 1.8 (n ¼ 15)
Week 40 36.0 6 1.6 37.0 6 1.4 37.9 6 2.3 36.9 6 2.0
WC (cm) Baseline 114.7 6 4.7 (n ¼ 13) 113.9 6 3.4 (n ¼ 14) 119.2 6 5.1 (n ¼ 14) 114.3 6 2.9 (n ¼ 13)
Week 40 114.6 6 5.0 113.7 6 3.9 115.6 6 5.4 110.4 6 3.5
WHR
a Baseline 1.00 6 0.01 (n ¼ 13) 0.97 6 0.03 (n ¼ 14) 0.99 6 0.02 (n ¼ 14) 1.00 6 0.02 (n ¼ 13)
Week 40 1.00 6 0.01 0.95 6 0.03 0.97 6 0.01 0.93 6 0.02
b
Glycohemoglobin (%) Baseline 5.5 6 0.1 (n ¼ 16) 5.5 6 0.1 (n ¼ 15) 5.8 6 0.1 (n ¼ 16) 5.6 6 0.2 (n ¼ 15)
Week 12 5.6 6 0.1 5.6 6 0.1 6.0 6 0.1 5.8 6 0.1
Week 40 5.8 6 0.1 5.7 6 0.1 6.0 6 0.1 5.9 6 0.1
Glucose area under the curve Baseline 1,596.1 6 57.1 (n ¼ 16) 1,605.3 6 41.8 (n ¼ 15) 1,668.7 6 50.5 (n ¼ 16) 1,573.9 6 48.4 (n ¼ 15)
Week 40 1,500.2 6 79.3 1,450.3 6 47.1 1,522.6 6 57.8 1,443.7 6 71.5
Values are means 6 SEM. Final anthropometric measurements were not obtained in some participants.
ap ¼ 0.028 for comparison of four treatment groups using analysis of variance for repeated measures.
bp ¼ , 0.01 within GH þ PIO group versus baseline.
doi:10.1371/journal.pctr.0020021.t004 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Figure 5. Effects of Four Different Interventions on Fasting Blood
Glucose in Abdominally Obese Adults with IGT
Week 43 FPG was obtained three to four weeks after drug washout. Values
are means 6 SEM. *p ¼ 0.01 for within GH group comparison of week 12
versus baseline FPG. **p ¼ 0.048 for comparison of four treatment groups
combined before and after 12 weeks of treatment using analysis of variance
for repeated measures.
doi:10.1371/journal.pctr.0020021.g005
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GH and TZD in Obese Prediabetic AdultsPIO-treated diabetics [48]. At present, the overall effect of
TZDs on visceral fat content remains uncertain.
Our sample size was likely not large enough or adequately
powered to detect signiﬁcant changes in glucose concen-
trations during PIO treatment [49]. Similarly, with regard to
multiple testing, the analysis of lipids was performed as an
ancillary test that was not prespeciﬁed in the protocol. The
lack of signiﬁcance in lipid changes with PIO in the present
study was seen in the context of a smaller subset of data
analyzed (only 13 participants per group). Therefore, the
possibility that the study was not adequately powered to see
changes in lipid parameters with PIO must be considered,
given that improvements in triglyceride and HDL cholesterol
have been reported in PIO-treated diabetics [50–51]. It is
unclear, however, if PIO exerts different effects on lipids in
diabetic versus nondiabetic adults such as the participants in
this study.
In the GH plus PIO group, mean FPG remained stable, and
both visceral fat and insulin resistance declined over time.
PIO attenuated the diabetogenic effect of GH shortly after
GH injections began and before any change in body
composition would have been expected. Further, the reduc-
tion in visceral fat area that occurred after 40 weeks of GH
plus PIO treatment (27 6 4c m
2) was similar to the reduction
that occurred with GH alone (24 6 7c m
2). Only cotreatment
with PIO resulted in improved insulin sensitivity, while GH
alone did not. These ﬁndings suggest an important role for
TZDs in improving insulin sensitivity [44].
Overall Evidence
The ﬁndings of this study can be reviewed in the context of
other similar clinical trials. We performed a Medline search
for clinical trials involving treatment with GH, a TZD, or both
in overweight and/or insulin-resistant adults who were non-
diabetic and were otherwise healthy. To facilitate better
comparisons with the current study, the search was restricted
to trials in which abdominal and visceral fat was directly
measured using CT scan or MRI, and the pharmacologic
intervention (GH or TZD) was not combined with lifestyle
modiﬁcation. Randomized controlled trials performed in a
community setting were identiﬁed. Our search (up to 1
February 2007) revealed eight publications that involved four
GH-treated cohorts and three TZD-treated cohorts.
In the GH trials [19,20,43,52,53], controls received a
placebo and treatment duration ranged from ﬁve weeks to
one year. Total abdominal or visceral fat declined signiﬁ-
cantly in men [19,43], while in women, a decline versus
placebo was seen in some [20,52], but not all [46] studies. In
addition, the magnitude of fat reduction observed with GH
was consistently greater in men than in women. Differences
in glucose metabolism were seen among studies that reported
these measured data. Except in one study [20], short-term
administration of GH transiently worsened insulin resistance
[19,53] and increased fasting glucose levels [53]. However,
prolonged GH administration was not associated with
deleterious changes in glucose tolerance or insulin sensitivity
[19,20], as was the case in the present study. The results for
lipid data are conﬂicting, with total cholesterol after six
.......................................................................................................................................................................................
Table 5. Lipid Measurements
Measurement Time Placebo (n ¼ 13) PIO (n ¼ 13) GH (n ¼ 13) GH þ PIO (n ¼ 13)
Triglycerides (mg/dl) Baseline 163.2 6 22 139.4 6 23.9 170.7 6 15.7 128 6 16.5
Week 40 178.2 6 26 129.3 6 24.2 159.2 6 11.8 127.5 6 17.5
HDL cholesterol (mg/dl) Baseline 40 6 1.9 44.2 6 3 40.3 6 1.7 43.4 6 2.3
Week 40 40.4 6 2.5 46.2 6 3.1 43.6 6 2.6 43.5 6 2.1
LDL cholesterol (mg/dl) Baseline 114.5 6 7.2 111.2 6 8.1 114.2 6 6.5 119 6 11.8
Week 40 114.7 6 7.2 103.5 6 9 111.2 6 7.5 122.2 6 10.6
Total cholesterol (mg/dl) Baseline 187 6 7.3 183.3 6 8.9 188.7 6 7.4 189.4 6 13
Week 40 190.9 6 6.6 175.6 6 7.3 187.3 6 8.5 191.1 6 10.6
Values are means 6 SEM. Performed on available stored samples from baseline and post-treatment visits. Results for week 40 were obtained 3–4 wk after drug washout. Lipid data for
three participants who started lipid-lowering drugs after entering study were not included in analysis.
doi:10.1371/journal.pctr.0020021.t005 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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Table 6. Fluid Retention Symptoms and Interventions
Group Fluid Retention Symptom
a (Number of Cases) Intervention
Placebo Lower extremity edema, 3þ pitting (1) Low-dose furosemide for 5 d
PIO Lower extremity edema, 1–2þ pitting (2) No intervention
GH Lower extremity edema, 1–2þ pitting (2) No intervention (one case)
GH dose reduced by 25% (one case)
Arthralgias, joint stiffness (4) No intervention (two cases)
GH dose reduced by 25% (two cases)
Carpal tunnel symptoms, paresthesias (1) GH dose reduced by 25%
GH þ PIO Lower extremity edema, 1–2þ pitting (5) No intervention (three cases)
PIO dose reduced by 50% (one case)
GH dose reduced by 25% (one case)
Arthralgias (1) GH dose reduced by 25%
aExtent of edema is indicated as 1–2þ pitting for mild-moderate swelling and   3þ pitting for severe swelling.
doi:10.1371/journal.pctr.0020021.t006 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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months of GH reported to be unchanged versus baseline in
men [19] and transiently decreased and subsequently return-
ing to baseline after one year of treatment in women [20].
In the TZD trials [54–56], treatment duration ranged from
ten to 20 weeks. We found two publications that involved PIO
[54,55], and one that involved troglitazone [56]. The control
groups received either a placebo [56], metformin [55], or diet
and exercise [54]. Insulin sensitivity improved in all cases [54–
56], indicating a potentially beneﬁcial role for TZDs in
overweight, nondiabetic, healthy adults. Conversely, visceral
fat content did not decline signiﬁcantly versus baseline or
controls in any of the studies. In the study that compared
TZD treatment to placebo [56], no signiﬁcant changes in
fasting or postprandial glucose levels were reported.
Although triglycerides decreased and LDL increased in
troglitazone-treated participants [56], changes in lipoprotein
levels over time were not seen with PIO in healthy,
overweight, nondiabetic volunteers [54,55].
In the current study, combined treatment with GH and PIO
resulted in estimated effect sizes for DVAT and DSSPG that
were similar to GH and PIO, respectively. We considered
whether the effect sizes seen in this trial might be an artifact
of multiple testing for statistical signiﬁcance, but this was not
thought to be important because (1) sample size and power
calculations were determined to see true differences in
primary outcome measures; and (2) the reduction in visceral
fat seen with GH (13.1%) and the decline in insulin resistance
with PIO (21.4%) are comparable with the results of others
and have been consistently well-documented in various
studies [19,20, 52–56]. Taken together, these ﬁndings suggest
that PIO improves insulin sensitivity in IGT adults and
complements the lipolytic effect of GH.
Generalizability
Moderate weight loss (2.3–4.5 kg) induced by diet and/or
exercise has been associated with reductions in insulin
resistance and VAT of as much as 15%–20% or more, similar
to that seen with GH þ PIO in the present study [9]. VAT
reduction and improved insulin action may not only be
important for preventing or delaying diabetes, but also for
modulating surrogate markers for cardiovascular disease and
improving cardiovascular outcome [8–10].
Given the rising costs and growing burden of diabetes on
the health-care system [57], strategies that aim to prevent or
delay the onset of this disease might be beneﬁcial [58].
Although diet plus exercise is frequently used in experimen-
tal settings and is the mainstay for body fat reduction, this
approach often fails in clinical situations and is commonly
associated with recidivism. For pharmacologic interventions
such as GH that might be useful in reducing body fat, cost and
side effects are important considerations. The average cost
for GH replacement in adults is widely regarded as
unacceptably high. However, the cost has declined in recent
years, in part because of evolving dosing strategies that have
steadily lowered initial GH doses used to achieve similar
efﬁcacy [59]. Similarly, GH-associated side effects are gen-
erally transient or are well tolerated, and treatment dis-
continuation is not common, particularly with the lower GH
doses that have been advocated in recent years [59]. Further,
the issue of cost with the use of GH in obesity must be
considered in the overall context of the soaring costs and
rising health-care burden of diabetes. Given the link between
visceral obesity, insulin resistance, and the risk for diabetes
and cardiovascular disease, future studies assessing the body
composition and metabolic effects of GHþPIO in adults with
the metabolic syndrome may be warranted.
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